基于 Venetoclax 的联合疗法治疗 CAR-T 治疗失败的复发/难治性弥漫性大 B 细胞淋巴瘤患者。
Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy.
机构信息
National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
College of Art and Science, New York University, New York City, NY, USA.
出版信息
Ann Hematol. 2023 Mar;102(3):597-601. doi: 10.1007/s00277-023-05088-7. Epub 2023 Jan 30.
There are few effective therapeutic options available for R/R DLBCL patients who have undergone CAR-T therapy. We retrospectively assessed 10 R/R DLBCL patients with complete clinical records who received venetoclax-based combination therapy following CAR-T therapy failed in our center between July 2020 and December 2021. After receiving CAR-T therapy, they all relapsed within a few months. As salvage regimens, they were all given venetoclax-based combination therapy. The objective response rate (ORR) was 80 percent, and the complete response rate was 30 percent. At the time of the analysis, 7 patients were still living. Our research has demonstrated that venetoclax-based combination treatment for R/R DLBCL patients who failed CAR-T therapy has a high effectiveness and manageable toxicity.
对于接受过 CAR-T 治疗后复发/难治性弥漫性大 B 细胞淋巴瘤（R/R DLBCL）患者，目前可用的有效治疗选择有限。我们回顾性评估了 2020 年 7 月至 2021 年 12 月在我们中心接受 CAR-T 治疗失败后接受 Venetoclax 为基础的联合治疗的 10 例有完整临床记录的 R/R DLBCL 患者。在接受 CAR-T 治疗后，他们均在几个月内复发。作为挽救性治疗方案，他们均接受 Venetoclax 为基础的联合治疗。客观缓解率（ORR）为 80%，完全缓解率为 30%。在分析时，7 例患者仍存活。我们的研究表明，对于接受 CAR-T 治疗失败的 R/R DLBCL 患者，Venetoclax 为基础的联合治疗具有较高的疗效和可管理的毒性。
Zotero 插件